82266-85-1

Usage

Uses

Since the provided materials do not specify any particular uses for (6aR,7R,9aR)-11-((3S,5R)-3,5-dihydroxy-2-Methylcyclohex-1-en-1-yl)-6a-Methyl-7-((R)-6-Methylheptan-2-yl)-2-phenyl-4a,5,6,6a,7,8,9,9a-octahydrocyclopenta[f][1,2,4]triazolo[1,2-a]cinnoline-1,3(2H,11H)-dione, we can only speculate on possible applications based on its structural features and potential pharmaceutical or biological activities. However, without specific information on its uses, we cannot list any applications for (6aR,7R,9aR)-11-((3S,5R)-3,5-dihydroxy-2-Methylcyclohex-1-en-1-yl)-6a-Methyl-7-((R)-6-Methylheptan-2-yl)-2-phenyl-4a,5,6,6a,7,8,9,9a-octahydrocyclopenta[f][1,2,4]triazolo[1,2-a]cinnoline-1,3(2H,11H)-dione.
For comparison, here is the example provided for Gallotannin:

Uses

Used in Anticancer Applications:
Gallotannin is employed as an anticancer agent, particularly against solid malignancies such as liver, breast, lung, pancreatic, colorectal, and ovarian cancers. It modulates several oncological signaling pathways, including JAK/STAT, RAS/RAF/mTOR, TGF-β1/TGF-β1R, VEGF/VEGFR, and CXCL12/CXCR4 axes, exerting inhibitory effects on tumor growth and progression. Additionally, it demonstrates synergistic anticancer effects when combined with conventional chemotherapeutic drugs, enhancing chemo-sensitivity and efficacy in resistant cases.
Used in Drug Delivery Systems:
To overcome the limitations of gallotannin, novel drug delivery systems have been developed to enhance its applications and efficacy against cancer cells. Various organic and metallic nanoparticles have been employed as carriers for gallotannin delivery, aiming to improve its delivery, bioavailability, and therapeutic outcomes.

Upstream product

• 82257-55-4 (3bR,5aR,6R,8aR,10S)-10-[(R)-5-(tert-Butyl-dimethyl-silanyloxy)-2-methyl-3-oxo-cyclohex-1-enyl]-6-((R)-1,5-dimethyl-hexyl)-5a-methyl-2-phenyl-4,5,5a,6,7,8,8a,10-octahydro-3bH-2,3a,10a-triaza-dicyclopenta[a,f]naphthalene-1,3-dione 
• 82283-42-9 (3bR,5aR,6R,8aR,10S)-10-[(S)-5-(tert-Butyl-dimethyl-silanyloxy)-2-methyl-cyclohex-1-enyl]-6-((R)-1,5-dimethyl-hexyl)-5a-methyl-2-phenyl-4,5,5a,6,7,8,8a,10-octahydro-3bH-2,3a,10a-triaza-dicyclopenta[a,f]naphthalene-1,3-dione 
• 82257-54-3 (3bR,5aR,6R,8aR,10S)-6-((R)-1,5-Dimethyl-hexyl)-10-((S)-5-hydroxy-2-methyl-cyclohex-1-enyl)-5a-methyl-2-phenyl-4,5,5a,6,7,8,8a,10-octahydro-3bH-2,3a,10a-triaza-dicyclopenta[a,f]naphthalene-1,3-dione 
• 1173-13-3 previtamin D₃ 
• 4233-33-4 4-Phenyl-1,2,4-triazolidine-3,5-dione 
• 138852-16-1 Butyric acid (1R,5S)-5-bromo-3-[(3bR,5aR,6R,8aR,10S)-6-((R)-1,5-dimethyl-hexyl)-5a-methyl-1,3-dioxo-2-phenyl-2,3,4,5,5a,6,7,8,8a,10-decahydro-1H,3bH-2,3a,10a-triaza-dicyclopenta[a,f]naphthalen-10-yl]-4-methyl-cyclohex-3-enyl ester 
• 86307-22-4 Butyric acid (S)-3-[(3bR,5aR,6R,8aR,10S)-6-((R)-1,5-dimethyl-hexyl)-5a-methyl-1,3-dioxo-2-phenyl-2,3,4,5,5a,6,7,8,8a,10-decahydro-1H,3bH-2,3a,10a-triaza-dicyclopenta[a,f]naphthalen-10-yl]-4-methyl-cyclohex-3-enyl ester 
• 138852-19-4 Butyric acid (1R,5S)-5-acetoxy-3-[(3bR,5aR,6R,8aR,10S)-6-((R)-1,5-dimethyl-hexyl)-5a-methyl-1,3-dioxo-2-phenyl-2,3,4,5,5a,6,7,8,8a,10-decahydro-1H,3bH-2,3a,10a-triaza-dicyclopenta[a,f]naphthalen-10-yl]-4-methyl-cyclohex-3-enyl ester 
• 82257-57-6 (3bR,5aR,6R,8aR,10S)-6-((R)-1,5-Dimethyl-hexyl)-10-((R)-5-hydroxy-2-methyl-3-oxo-cyclohex-1-enyl)-5a-methyl-2-phenyl-4,5,5a,6,7,8,8a,10-octahydro-3bH-2,3a,10a-triaza-dicyclopenta[a,f]naphthalene-1,3-dione 

Downstream Products

• 41461-13-6 1α-hydroxyprecalciferol₃ 
• 41294-56-8 1α-hydroxyvitamin D3 

Relevant academic research and scientific papers

An Improved Synthesis of 1α-hydroxy Vitamin D3

The efficient and stereoselective introduction of the 1α-OH function in vitamin D3 is described starting from the known previtamin D3 adduct 6.The sequence involves the stereoselective allylic bromination to 9, followed by substituti